Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent...

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• Transforming growth factor-beta1 (TGF-beta) plays a dual role in cancer, potentially suppressing tumors or promoting progression.
• TGF-beta-induced epithelial-to-mesenchymal transition (EMT) is a critical process in tumor metastasis, but the underlying signaling pathways remain incompletely understood.

Purpose of the Study:

• To elucidate the specific signaling pathways regulated by TGF-beta that mediate EMT in mammary epithelial cells.
• To identify key molecular players involved in TGF-beta-induced mesenchymal differentiation.

Main Methods:

• Assessed TGF-beta-induced EMT markers including fibroblastoid morphology, N-cadherin expression, E-cadherin localization, and cellular motility.
• Utilized dominant-negative Smad3 and Smad7 to investigate Smad-dependent pathways.
• Examined the role of RhoA and its downstream effector p160(ROCK) using dominant-negative mutants.

Main Results:

• TGF-beta induced EMT markers, but Smad3 inhibition or Smad7 overexpression did not prevent mesenchymal differentiation.
• TGF-beta rapidly activated RhoA signaling in epithelial cells.
• Inhibition of RhoA or p160(ROCK) effectively blocked TGF-beta-mediated EMT.

Conclusions:

• TGF-beta utilizes RhoA-dependent signaling pathways, not Smad3 or Smad7, to rapidly induce EMT.
• Activation of RhoA and subsequent stress fiber formation are critical for mesenchymal characteristics during TGF-beta-induced EMT.